CLINICAL TRIALS PROFILE FOR METAGLIP
✉ Email this page to a colleague
All Clinical Trials for METAGLIP
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00648505 ↗ | Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed conditions. |
| NCT00649454 ↗ | Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions. |
| NCT00834587 ↗ | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-06-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under non-fasting conditions. |
| NCT00835497 ↗ | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-06-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METAGLIP
Condition Name
Clinical Trial Locations for METAGLIP
Trials by Country
Clinical Trial Progress for METAGLIP
Clinical Trial Phase
Clinical Trial Sponsors for METAGLIP
Sponsor Name
